Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Share-based Compensation (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Share-based Compensation for 8 consecutive years, with $8.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 4.68% year-over-year to $8.8 million, compared with a TTM value of $38.1 million through Sep 2025, up 7.27%, and an annual FY2024 reading of $38.1 million, up 17.26% over the prior year.
  • Share-based Compensation was $8.8 million for Q3 2025 at Bicycle Therapeutics, down from $9.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.3 million in Q4 2024 and bottomed at $2.6 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $7.2 million, with a median of $8.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 166.89% in 2022, then dropped 11.34% in 2023.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then skyrocketed by 84.73% to $5.5 million in 2022, then soared by 41.01% to $7.8 million in 2023, then soared by 32.27% to $10.3 million in 2024, then fell by 15.12% to $8.8 million in 2025.
  • Business Quant data shows Share-based Compensation for BCYC at $8.8 million in Q3 2025, $9.4 million in Q2 2025, and $9.6 million in Q1 2025.